Seamus Mulligan, Director at Jazz Pharmaceuticals plc (JAZZ), bought 98,500 shares at $145.05 ($14.2M) on 2018-11-15, disclosed to the SEC on 2018-11-19.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $141.86 | 300 | $43K | 0.3% |
| 2 | $143.22 | 1,200 | $172K | 1.2% |
| 3 | $144.24 | 26,363 | $3.8M | 26.7% |
| 4 | $144.24 | 26,363 | $3.8M | 26.7% |
| 5 | $145.05 | 22,137 | $3.2M | 22.5% |
| 6 | $145.05 | 22,137 |
| $3.2M |
| 22.5% |
| Total | $144.58 avg | 98,500 | $14.2M | 100% |
| Filing → |
| JAZZ | SELL | 2016-08-26 | $6.0M | — | Filing → |
| JAZZ | SELL | 2016-05-26 | $8.2M | — | Filing → |
| JAZZ | SELL | 2016-02-24 | $6.9M | — | Filing → |